Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma

British Journal of Haematology

Volumn 141, Issue 2, 2008, Pages 235-243

  Ingram, Wendy ^a   Devereux, Stephen ^a   Das Gupta, Emma P ^b   Russell, Nigel H ^b   Haynes, Andrew P ^b   Byrne, Jennifer L ^b   Shaw, Bronwen E ^b   McMillan, Andrew ^b   Gonzalez, Juan ^a   Ho, Aloysius ^a   Mufti, Ghulam J ^a   Pagliuca, Antonio ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Alemtuzumab; Allogeneic HSCT; Autologous HSCT; Follicular lymphoma

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADVANCED CANCER; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CANCER STAGING; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 40949125732     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07067.x     Document Type: Article

References (43)

1. Bastion, Y., Brice, P., Haioun, C., Sonet, A., Salles, G., Marolleau, J.P., Espinouse, D., Reyes, F., Gisselbrecht, C. Coiffier, B. (1995) Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood, 86, 3257 3262.
2. van Besien, K.W., de Lima, M., Giralt, S.A., Moore, Jr., D.F., Khouri, I.F., Rondon, G., Mehra, R., Andersson, B.S., Dyer, C., Cleary, K., Przepiorka, D., Gajewski, J.L. Champlin, R.E. (1997) Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation, 19, 977 982.
3. van Besien, K., Loberiza, Jr., F.R., Bajorunaite, R., Armitage, J.O., Bashey, A., Burns, L.J., Freytes, C.O., Gibson, J., Horowitz, M.M., Inwards, D.J., Marks, D.I., Martino, R., Maziarz, R.T., Molina, A., Pavlovsky, S., Pecora, A.L., Schouten, H.C., Shea, T.C., Lazarus, H.M., Rizzo, J.D. Vose, J.M. (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 102, 3521 3529.
4. Branson, K., Chopra, R., Kottaridis, P.D., McQuaker, G., Parker, A., Schey, S., Chakraverty, R.K., Craddock, C., Milligan, D.W., Pettengell, R., Marsh, J.C., Linch, D.C., Goldstone, A.H., Williams, C.D. Mackinnon, S. (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. Journal of Clinical Oncology, 20, 4022 4031.
5. Chakrabarti, S., Avivi, I., Mackinnon, S., Ward, K., Kottaridis, P.D., Osman, H., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. Milligan, D.W. (2002a) Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. British Journal of Haematology, 119, 1125 1132.
6. Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O'Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. Milligan, D.W. (2002b) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 4357 4363.
7. Chakrabarti, S., Mautner, V., Osman, H., Collingham, K.E., Fegan, C.D., Klapper, P.E., Moss, P.A. Milligan, D.W. (2002c) Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood, 100, 1619 1627.
8. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244 1253.
9. Chopra, R., McMillan, A.K., Linch, D.C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K.G. Goldstone, A.H. (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood, 81, 1137 1145.
10. Cull, G.M., Haynes, A.P., Byrne, J.L., Carter, G.I., Miflin, G., Rebello, P., Hale, G., Waldmann, H. Russell, N.H. (2000) Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. British Journal of Haematology, 108, 754 760.
11. Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P., Cornillet-LeFebvre, P., Escoffre-Barbe, M., Maisonneuve, H., Delwail, V., Gressin, R., Legouffe, E., Vilque, J.P., Desablens, B., Jaubert, J., Ramee, J.F., Jenabian, A., Thyss, A., Le Pourhiet-Le Mevel, A., Travade, P., Delepine, R. Colombat, P. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood, 105, 3817 3823.
12. Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. Russell, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428 434.
13. Freedman, A.S., Neuberg, D., Mauch, P., Soiffer, R.J., Anderson, K.C., Fisher, D.C., Schlossman, R., Alyea, E.P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L.M. Gribben, J.G. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94, 3325 3333.
14. Gallagher, C.J., Gregory, W.M., Jones, A.E., Stansfeld, A.G., Richards, M.A., Dhaliwal, H.S., Malpas, J.S. Lister, T.A. (1986) Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology, 4, 1470 1480.
15. Ho, A.Y., Devereux, S., Mufti, G.J. Pagliuca, A. (2003) Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. Bone Marrow Transplantation, 31, 551 557.
16. Horning, S.J. Rosenberg, S.A. (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. The New England Journal of Medicine, 311, 1471 1475.
17. Howe, R., Micallef, I.N., Inwards, D.J., Ansell, S.M., Dewald, G.W., Dispenzieri, A., Gastineau, D.A., Gertz, M.A., Geyer, S.M., Hanson, C.A., Lacy, M.Q., Tefferi, A. Litzow, M.R. (2003) Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplantation, 32, 317 324.
18. Hunault-Berger, M., Ifrah, N. Solal-Celigny, P. (2002) Intensive therapies in follicular non-Hodgkin lymphomas. Blood, 100, 1141 1152.
19. Jaffe, E.S., Harris, N.L., Stein, H. Vardiman, J.W. (2001) Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissue. IARC Press, Lyon.
20. Johnson, P.W., Rohatiner, A.Z., Whelan, J.S., Price, C.G., Love, S., Lim, J., Matthews, J., Norton, A.J., Amess, J.A. Lister, T.A. (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. Journal of Clinical Oncology, 13, 140 147.
21. Jones, R.J., Ambinder, R.F., Piantadosi, S. Santos, G.W. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, 649 653.
22. Khouri, I.F., Saliba, R.M., Giralt, S.A., Lee, M.S., Okoroji, G.J., Hagemeister, F.B., Korbling, M., Younes, A., Ippoliti, C., Gajewski, J.L., McLaughlin, P., Anderlini, P., Donato, M.L., Cabanillas, F.F. Champlin, R.E. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 98, 3595 3599.
23. Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointner, R., Wandt, H., Freund, M., Hess, G., Truemper, L., Diehl, V., Kropff, M., Kneba, M., Schmitz, N., Metzner, B., Pfirrmann, M., Unterhalt, M. Hiddemann, W. (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood, 104, 2667 2674.
24. Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rankin, E., Stahel, R., Uppenkamp, M., Willemze, R. Mellstedt, H. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 16, 3257 3263.
25. Mandigers, C.M., Meijerink, J.P., Raemaekers, J.M., Schattenberg, A.V. Mensink, E.J. (1998) Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet, 352, 1522 1523.
26. Mandigers, C.M., Verdonck, L.F., Meijerink, J.P., Dekker, A.W., Schattenberg, A.V. Raemaekers, J.M. (2003) Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplantation, 32, 1159 1163.
27. Martino, R., Caballero, M.D., Canals, C., Simon, J.A., Solano, C., Urbano-Ispizua, A., Bargay, J., Rayon, C., Leon, A., Sarra, J., Odriozola, J., Conde, J.G., Sierra, J. San Miguel, J. (2001) Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. British Journal of Haematology, 115, 653 659.
28. Micallef, I.N., Lillington, D.M., Apostolidis, J., Amess, J.A., Neat, M., Matthews, J., Clark, T., Foran, J.M., Salam, A., Lister, T.A. Rohatiner, A.Z. (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. Journal of Clinical Oncology, 18, 947 955.
29. Mijovic, A., Parker, J., Salisbury, J., Pagliuca, A. Mufti, G.J. (1998) Autologous blood or bone marrow transplantation for relapsed and partially responding low-grade non-hodgkin's lymphoma. Cancer Research Therapy and Control, 5, 253 260.
30. Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. Goldstone, A.H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 13, 588 595.
31. Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 3865 3871.
32. National Cancer Institute (1999) Cancer Therapy Evaluation Programme, Common Toxicity Criteria Manual, Common Toxicity Criteria, Version 2.0. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
33. Parimon, T., Au, D.H., Martin, P.J. Chien, J.W. (2006) A risk score for mortality after allogeneic hematopoietic cell transplantation. Annals of Internal Medicine, 144, 407 414.
34. Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F. Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 3121 3127.
35. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. Thomas, E.D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825 828.
36. Ratanatharathorn, V., Uberti, J., Karanes, C., Abella, E., Lum, L.G., Momin, F., Cummings, G. Sensenbrenner, L.L. (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood, 84, 1050 1055.
37. Rodig, S.J., Abramson, J.S., Pinkus, G.S., Treon, S.P., Dorfman, D.M., Dong, H.Y., Shipp, M.A. Kutok, J.L. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clinical Cancer Research, 12, 7174 7179.
38. Salisbury, J.R., Rapson, N.T., Codd, J.D., Rogers, M.V. Nethersell, A.B. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. Journal of Clinical Pathology, 47, 313 317.
39. Schouten, H.C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnson, H.E., Doorduijn, J.K., Sydes, M.R. Kvalheim, G. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology, 21, 3918 3927.
40. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912 2919.
41. Valcarcel, D., Martino, R., Sureda, A., Canals, C., Altes, A., Briones, J., Sanz, M.A., Parody, R., Constans, M., Villela, S.L., Brunet, S. Sierra, J. (2005) Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. European Journal of Haematology, 74, 144 151.
42. Verdonck, L.F., Dekker, A.W., Lokhorst, H.M., Petersen, E.J. Nieuwenhuis, H.K. (1997) Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood, 90, 4201 4205.
43. Vigouroux, S., Michallet, M., Porcher, R., Attal, M., Ades, L., Bernard, M., Blaise, D., Tabrizi, R., Garban, F., Cassuto, J.P., Chevalier, P., Facon, T., Ifrah, N., Renaud, M., Tilly, H., Vernant, J.P., Kuentz, M., Bourhis, J.H., Bordigoni, P., Deconinck, E., Lioure, B., Socie, G. Milpied, N. (2007) Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica, 92, 627 634.